Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspecs Group Regulatory News (SPEC)

Share Price Information for Inspecs Group (SPEC)

Share Price is delayed by 15 minutes
Get Live Data
84.50    0.00 (0.00%)
Bid:
82.00
Ask:
87.00
Spread: 5.00 (6.098%)
Market Cap: £85.91m
SPEC Live PriceLast checked at - London Stock Exchange

Intraday Inspecs Group Share Chart

Trading Update

30 Jan 2025 07:00

RNS Number : 1945V
Inspecs Group PLC
30 January 2025
 

30 January 2025

Inspecs Group plc

("INSPECS" or "the Group")

 

Full Year Trading Update

 

Inspecs Group plc, a leading designer, manufacturer and distributor of eyewear (sunglasses, optical frames, lenses and low vision products), today announces a trading update for the year ended 31 December 2024 ahead of reporting its final results on 10 April 2025.

 

Summary

·

Group revenue of £200.5m (2023: £203.3m) and Underlying EBITDA of £17.5m (2023: £18.0m)

·

H2 2024 revenue increase of 5.9% to £97.5m (H2 2023: £92.1m)

·

Gross profit margin increased from 50.9% to 51.4%

·

Reduced net debt (excluding leases) by £1.3m to £22.9m (2023: £24.2m)

·

Integration of US businesses completed in 2024 and now fully amalgamated

·

The new facility in Vietnam is now fully operational, with promising enquiries to utilise the enlarged manufacturing capacity

·

Eschenbach Optics division has performed strongly, particularly in the US and Europe, with our new digital low vision aids well received by the market

·

European business continues to take market share despite an overall soft market

·

Renewed and extended Group banking facilities to 2027 with HSBC

 

Revenue and Underlying EBITDA

Group revenue for the year was £200.5m (2023: £203.3m) and on a constant currency basis1, revenue increased £2.3m to £205.6m. The Group expects to deliver an Underlying EBITDA of £17.5m (2023: £18.0m) in line with recently updated market expectations2. The Group is targeting revenue growth in 2025 together with improving EBITDA margin as key priorities.

 

Financial position

The Group's net debt (excluding leases) decreased by £1.3m during the year to £22.9m (31 December 2023: £24.2m). The Group invested a further £0.7m in the new Vietnam factory as planned to provide additional capacity with improved sustainable efficiency, and a further £1.9m on deferred and contingent acquisition consideration.

 

Financial funding and liquidity

The Group successfully refinanced its existing banking arrangements with HSBC UK Bank plc in December, extending their maturity to 2027.

 

The debt facilities consist of a three-year Multicurrency Revolving Credit Facility and a Term Loan predominantly drawn in Euros and, as a result, the Group expects to reduce its interest costs in 2025 by circa £0.6m compared to 2024.

 

Outlook

The Group will continue to focus on delivering further operational efficiencies and reducing costs, while also reducing net debt and leverage. Whilst 2024 did not meet the full expectations of the Board, our US business delivered good growth during the year. The Group has made a solid start to 2025 and is confident of its ability to continue to reduce debt and increase margins and Underlying EBITDA.

 

Richard Peck, Chief Executive Officer commented:

"Whilst total revenue and Underlying EBITDA for the Group in 2024 was behind our original expectations, revenue growth was achieved in the second half of the year. I am also pleased that the Group increased its gross profit margin for the full year. During the period, we continued to focus on our operational efficiencies and, despite the inflationary pressures experienced in 2024, our operational costs have remained flat. The Group has also reduced net debt while investing in significant additional manufacturing capacity which is now operational, following the successful completion of construction in Vietnam.

 

"2025 has started well and our key objectives for the year are to raise the Group's revenue and increase our Underlying EBITDA margins across the Group while continuing to reduce our net debt."

 

 

1. Constant exchange rates: figures at constant exchange rates have been calculated using the average exchange rates in effect for the corresponding period in the relevant comparative year.

2. Company compiled market expectation - Revenue c.£197m and Underlying EBITDA £17.4m to £17.9m.

 

For further information please contact:

Inspecs Group plc

Richard Peck (CEO)

Chris Kay (CFO)

 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

George Sellar

Andrew Clark

 

 

Tel: +44 (0) 20 7418 8900

FTI Consulting (Financial PR)

Alex Beagley

Harriet Jackson

Amy Goldup

 

 

Tel: +44 (0) 20 3727 1000

About INSPECS Group plc

INSPECS is a leading provider of eyewear solutions to the global eyewear market. The Group produces a broad range of eyewear frames, low vision aids and lenses, covering optical, sunglasses and safety, which are either "Branded" (under licence or under the Group's own proprietary brands), or "OEM" (unbranded or private label on behalf of retail customers).

INSPECS is building a global eyewear business through its vertically integrated business model. Its continued growth is underpinned by six core pillars: increasing the penetration of its own-brand portfolio, increasing distribution, growing its travel retail markets, maximising group synergies, expanding its manufacturing capacity and scaling the research and development department as it develops new and innovative eyewear products. The Group has operations across the globe: with offices and subsidiaries in the UK, Germany, Portugal, Scandinavia, the US and China (including Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy.

INSPECS customers are global optical and non-optical retailers, global distributors and independent opticians. Its distribution network covers over 80 countries and reaches approximately 75,000 points of sale.

More information is available at: www.INSPECS.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKCBPCBKDODB
Date   Source Headline
12th Jun 20241:59 pmRNSHolding(s) in Company
6th Jun 20241:54 pmRNSResult of AGM
6th Jun 20247:00 amRNSAGM Statement
14th May 20241:49 pmRNSPosting of Annual Report and Notice of AGM
23rd Apr 20243:57 pmRNSHolding(s) in Company
19th Apr 20249:35 amRNSHolding(s) in Company
17th Apr 20247:00 amRNSFinal Results
29th Jan 20247:00 amRNSFull Year Trading Update
11th Jan 20242:10 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSTrading Update
20th Sep 202311:14 amRNSHolding(s) in Company
7th Sep 20237:00 amRNSInterim Results
28th Jul 20237:00 amRNSHalf Year Trading Update
15th Jun 20233:36 pmRNSResult of AGM
22nd May 20231:16 pmRNSNotice of AGM
3rd May 20232:42 pmRNSUpdate on Full Year Results
28th Apr 20231:36 pmRNSDirector/PDMR Share Dealing
27th Apr 20237:00 amRNSPreliminary Unaudited Results
19th Apr 202312:24 pmRNSHolding(s) in Company
23rd Mar 20237:00 amRNSHolding(s) in Company
14th Mar 20233:15 pmRNSHolding(s) in Company
30th Jan 20233:18 pmRNSHolding(s) in Company
27th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSFull Year Trading Update
22nd Dec 20227:00 amRNSHolding(s) in Company
21st Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAppointment of Non-Executive Directors
25th Nov 20224:41 pmRNSSecond Price Monitoring Extn
25th Nov 20224:35 pmRNSPrice Monitoring Extension
11th Nov 202211:05 amRNSSecond Price Monitoring Extn
11th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20223:33 pmRNSHolding(s) in Company
8th Nov 20222:06 pmRNSSecond Price Monitoring Extn
8th Nov 20222:00 pmRNSPrice Monitoring Extension
8th Nov 20227:00 amRNSDirector/PDMR Share Dealing
3rd Nov 20227:00 amRNSDirector/PDMR Share Dealing
31st Oct 20223:05 pmRNSDirector/PDMR Shareholding
28th Oct 20226:25 pmRNSDirector/PDMR Shareholding - Replacement
28th Oct 20223:25 pmRNSDirector/PDMR Shareholding
27th Oct 20222:06 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
27th Oct 20229:05 amRNSSecond Price Monitoring Extn
27th Oct 20229:00 amRNSPrice Monitoring Extension
27th Oct 20227:00 amRNSTrading Update and Board Changes
20th Oct 202211:12 amRNSHolding(s) in Company
19th Oct 20224:18 pmRNSHolding(s) in Company
15th Sep 20225:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.